bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical
Marcy l’Étoile, France – April 4th, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers. In particular, Astute developed the NEPHROCHECK® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI) based on the level of two biomarkers, IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) and TIMP-2 (Tissue Inhibitor Metalloproteinases-2).
bioMérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS
With more than 15,000 distinct strains, VITEK® MS provides the microbiology lab with the most comprehensive Mass Spectrometry database to improve clinical decision-making for infectious diseases
- Legal Notice
- Copyright 2022 bioMérieux SA